For patients with idiopathic interstitial pneumonia-associated pulmonary hypertension, treatment with riociguat (Adempas) was not beneficial compared to placebo, and increased adverse events.
For patients with idiopathic interstitial pneumonia-associated pulmonary hypertension, treatment with riociguat (Adempas) was not beneficial compared to placebo, and increased adverse events.
Read More
According to results from the MOTION study, improvements were seen across several patient-reported outcomes for patients with pulmonary arterial hypertension (PAH) treated with Riociguat (Adempas).
Read MoreBayer has enrolled the first patient in a global Phase IV study assessing the clinical effects of riociguat in patients with pulmonary arterial hypertension (PAH).
Read More
Bayer will present clinical data from on riociguat (Adempas), which is approved to treat pulmonary arterial hypertension (PAH), at ATS 2017 in Washington DC.
Read More
The European Medicines Agency has advised that Adempas (riociguat) should not be prescribed to patients with pulmonary hypertension (PH) associated with idiopathic interstitial pneumonia.
Read More
The results from an ongoing Phase 3 study supports the long-term use of riociguat in patients with chronic thromboembolic pulmonary hypertension (CTEPH).
Read More
Several new pharmacological treatments for COPD and asthma have appeared on the respiratory market in the past year but what are the advantages these new generation pharmaceuticals?
Read More
Bayer Pharmaceuticals is terminating its Phase II study investigating riociguat in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias.
Read MoreRiociguat can be a treatment option for PAH patients with chronic thromboembolic pulmonary hypertension (CTEPH).
Read More
After a year of being treated with a novel drug, Riociguat, patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH), and those with persistent or recurrent pulmonary hypertension after an operation for the disease, showed sustained improvement.
Read MoreThe drug, ricoiguat, could prove effective as a treatment option for patients with PAH.
Read More
